Evidence map›Paper›PMID 40310566›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025

Medication regimen complexity in cancer patients: an overlooked issue for healthcare team.

Sude Ayca Cifci, Elif Aras Atik, Ömer Dizdar, Aygin Bayraktar-Ekincioglu

Abstract read
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sude Ayca CifciFaculty of Pharmacy, Department of Clinical Pharmacy, Hacettepe University, Sihhiye, Ankara, 06100, Turkey.ORCID http://orcid.org/0000-0002-0631-0056
Elif Aras AtikFaculty of Pharmacy, Department of Clinical Pharmacy, Hacettepe University, Sihhiye, Ankara, 06100, Turkey.ORCID http://orcid.org/0000-0001-8667-6623
Ömer DizdarInstitute of Oncology, Department of Medical Oncology, Hacettepe University, Ankara, Turkey.ORCID http://orcid.org/0000-0003-0911-9078
Aygin Bayraktar-EkinciogluFaculty of Pharmacy, Department of Clinical Pharmacy, Hacettepe University, Sihhiye, Ankara, 06100, Turkey. aygin@hacettepe.edu.tr.ORCID http://orcid.org/0000-0002-3481-0074

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe primary aim of this study was to assess the medication regimen complexity in patients with cancer and the change in complexity from admission to discharge. The secondary aim of the study was to explore the impact of medication complexity on the length of hospital stay, patients' perceived medication burden, adherence, and unplanned hospitalizations after discharge.

methodsThis study was prospectively conducted in medical oncology clinics of a tertiary care hospital. Patients over 18 years of age and diagnosed with solid tumors and deemed non-palliative were included. A clinical pharmacist assessed the patient's medication regimen complexity using the medication regimen complexity index (MRCI) upon admission, at 48 h of hospitalization, and at discharge. The clinical pharmacist also participated in the patient education provided by the multidisciplinary team at discharge. Patients' adherence was assessed by the medication adherence reporting scale (MARS) at admission and at the first outpatient visit after the discharge. The perceived burden of drug treatment by the patients was assessed using a questionnaire named the medication complexity questionnaire from patient perspective (MCQPP) that was designed by the researchers. The questionnaire was administered at the first follow-up visit at the outpatient clinic after the discharge. Unplanned hospitalizations of the patients within 30 days after discharge were also examined.

resultsA total of 147 patients were enrolled. The median (IQR) MRCI score at discharge was 15.0 (11.0-22.0), which was significantly higher than the MRCI score at admission, which was 11.0 (7.0-15.0) (p < 0.001). As a result of the patient education provided at discharge by the multidisciplinary team, a statistically significant increase was observed in the treatment adherence of the patients. The median (IQR) MARS score assessed at admission was 19 (15-23), while it increased to 20 (16-23) at the follow-up outpatient visit (p = 0.003). Complexity was found to be higher in patients who had more negative perceptions about their medication, in patients who reported that their daily life was significantly affected by their medication, and in those who perceived more significant burden when complex instructions for medication use were evident (p < 0.001). The median MRCI scores at discharge were higher in patients with unplanned hospitalizations compared to those without hospitalization (p < 0.001).

conclusionsIn conclusion, integrating the MRCI into oncology practices, along with multidisciplinary care that includes clinical pharmacists, may enable the identification of high-risk patients, the individualization of drug treatment, and the optimization of the treatment process.

Indexed as

Antineoplastic AgentsNeoplasmsPatient Care TeamAdultAgedAged, 80 and overFemaleHospitalizationHumansLength of StayMaleMedication AdherenceMiddle AgedPatient DischargePatient Education as TopicPharmacistsAntineoplastic AgentsAdherenceMedication burdenMedication regimen complexityUnplanned hospitalization

Identifiers

PMID40310566
PMCPMC12045823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.